What is the share price of Pfizer (PFE)?

Pfizer last traded at $25.05 (-0.4% on the day), as of 7/17/2026. For education only, not investment advice.

What is the P/E ratio of PFE?

Pfizer trades at a trailing P/E of about 11.8.

Pfizer

PFE · NYSE · Pharma · United States

$25.05-0.4%

Delayed · as reported by Yahoo Finance · as of Jul 17, 2026, 8:01 PM

Snapshot

TickerPFE

ExchangeNYSE

SectorPharma

IndustryDrug Manufacturers - General

CountryUnited States

Employees75,000

HeadquartersNew York, United States

Market cap$142.8B

P/E (TTM)11.8

P/B1.6

Volume40.13M

Websitewww.pfizer.com

Filings tracked6

About Pfizer — read

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.1%
Institutions69.5%
Public & other30.4%

3,696 institutional holders

As reported by Yahoo Finance.

Forensic check

Cash conversion · 3y1.85×

Cumulative operating cash flow ÷ cumulative net profit over 3 reported years ($33.1B vs $17.9B).

Above 1.0× means reported profit was more than covered by cash the business actually generated. Below 1.0× over several years means profit isn’t converting to cash — commonly explained by working capital funding growth, and worth reading alongside the cash-flow statement.

Computed by MarketChacha from reported annual figures (SEC XBRL). Not a rating or recommendation.

$23.1152-wk range$28.75

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Market cap

$142.8B

Day change

-0.4%

P/E (TTM)

11.8

Fwd P/E

8.8

P/B

1.6

Div yield

6.87%

Beta

0.31

ROE

9.0%

Profit CAGR (2y)

+91.5%

EPS (FY2025)

1.36

Net profit (FY2025)

$7.8B

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about PFE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	—	$7.8B	1.36	—	9.0%
FY2024	—	$8.0B	1.41	—	9.1%
FY2023	$50.9B	$2.1B	0.37	4.2%	2.4%

Quarterly

Period	Net profit	EPS
2026Q1	$2.7B	0.47
2025Q3	$3.5B	0.62
2025Q2	$2.9B	0.51
2025Q1	$3.0B	0.52
2024Q3	$4.5B	0.78
2024Q2	$41.0M	0.01
2024Q1	$3.1B	0.55
2023Q4	$-2.4B	-0.42
2023Q3	$2.3B	0.41
2023Q2	$5.5B	0.97

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Exhibits
SEC6/18/2026material
8-K — Reg FD disclosure
SEC6/18/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Shareholder vote results
SEC4/27/2026material
10-K filing
SEC2/26/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.